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ABSTRACT
Alternative splicing of the bcl-x gene generates two
transcripts: the anti-apoptotic bcl-xL isoform and the
10 pro-apoptotic bcl-xS isoform. The ratio between the
two isoforms is a key factor in development and in
cancer progression. Here, we show that a short anti-
sense chimeric peptide nucleic acid (PNA) oligonuc-
leotide conjugated to a polypeptide containing eight
15 Ser-Arg repeats (SR)8 can modulate splicing of bcl-x
both in vitro and in vivo and induces apoptosis in
HeLacells.ThePNA-SRoligowastargetedtoaregion
of bcl-x that does not contain splicing regulatory
sequences and was able to override the complex net-
20 work of splicing enhancers and silencers that regu-
lates the ratio between the two bcl-x isoforms. Thus,
PNA-SR oligos are powerful tools that can potentially
modulate splice site choice in endogenous genes
independent of the presence of other splicing regu-
25 latory mechanisms on the target gene.
INTRODUCTION
Analysis of the human genome indicates that at least 65% of
human genes are alternatively spliced (1), which contributes
signiﬁcantly to the complexity of the human proteome. The
30 understandingofthe mechanismsthatregulatealternative spli-
cing and the development of novel technologies to modulate
splicing patterns thus have great therapeutic potential in the
treatmentsofcancer,aswellasgeneticandinfectiousdiseases.
In tumors, the alternative splicing pattern of several genes,
35 including bcl-x, can undergo dramatic changes. Bcl-x is a
member of the bcl-2 family of apoptosis regulators and altern-
ative splicing of the bcl-x pre-mRNA generates two main
transcripts, a long (bcl-xL) and a short (bcl-xS) isoform,
that encode proteins with antagonistic functions (2). Bcl-xL
40 inhibits apoptosis through heterodimerization with pro-
apoptotic proteins (3), whereas bcl-xS has pro-apoptotic prop-
erties. A proper expression ratio between isoforms is essential
in several physiological and developmental processes, such as
thymic selection, mammary gland involution and neural
45 reshaping (4,5).
Bcl-xL is over-expressed in numerous types of cancer
including myelomas, lymphomas, hepatomas, neuroblastomas
and breast cancers (6–10). This over-expression of bcl-xL is
associated with decreased apoptosis in tumors, resistance to
50 chemotherapeutic drugs and a poor clinical outcome. Since
bcl-xS over-expression can induce apoptosis in tumoral cell
lines (11), the ability to alter the bcl-xL/-xS ratio thus has great
therapeutic potential for the treatment of cancer. Previous
work has shown that antisense oligonucleotides targeted to
55 the bcl-xL 50 splice site can decrease the expression of
bcl-xL while increasing bcl-xS expression, thus inducing
cell death in response to apoptotic signals (12,13).
However promising, the use of antisense oligonucleotides
targeted to splice junctions is not always a suitable approach to
60 alter the splicing pattern of a gene. The blockage of a splice
site can result in the activation of a nearby cryptic splice site,
which often leadsto the appearanceof mRNAs which translate
for truncated or modiﬁed proteins. Additionally, a splice site
block can cause unspliced mRNAs to be produced that are
65 subject to rapid nuclear degradation. It is also conceivable that
several unrelated genes could be inadvertently targeted by
the same antisense oligonucleotide because 50 splice site
sequences have a high degree of conservation.
A different approach to affect splicing regulation,
70 developed by Cartegni and Krainer (14), utilizes a new
class of compounds that mimic SR protein function. SR pro-
teins regulate splicing by binding to exonic sequences named
exonic splicing enhancers (ESEs) and recruiting components
of the splicing machinery to adjacent 50 and 30 splice sites (15).
75 The Ser-Arg (SR)-rich domains present at the C-termini of SR
proteins mediate such protein–protein interactions. Chimeric
antisense peptide nucleic acid (PNA) oligonucleotides (16)
*To whom correspondence should be addressed. Tel: +1 561 297 0627; Fax: +1 561 297 2221; Email: mcaputi@fau.edu
Present address:
Jeremy E. Wilusz, Watson School of Biological Sciences, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
  The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
areattributedastheoriginalplaceofpublicationwiththecorrectcitationdetailsgiven;ifanarticleissubsequentlyreproducedordisseminatednotinitsentiretybut
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
Nucleic Acids Research, 2005, Vol. 33, No. 20 6547–6554
doi:10.1093/nar/gki960linked to a polypeptide containing 5–10 Ser-Arg repeats have
been shown in vitro to activate splicing of substrates derived
from the BRCA1 and SMN2 genes (14).
It is unclear whether splicing activation by the chimeric
5 PNA-SR oligos is dependent on the presence of pre-
existingsplicingregulatoryelementsoronitstargetedposition
relative to the splice sites. In both the SMN2 and BRCA1
substrates, the targeted sequence was a previously character-
ized ESE, located a few nucleotides downstream of a 30 splice
10 site, which had been mutated to abolish splicing (14). Further-
more, it is unknown whether the PNA-SR oligos can be
delivered to cellular systems to activate splicing in complex
endogenous transcripts.
In this work, we utilized an in vitro splicing substrate
15 derived from the bcl-x gene to determine that PNA-SR oligos
are suitable tools to activate splicing independent of the pres-
ence of pre-existing splicing enhancers and silencers in the
target gene sequence. We also determined that a chimeric
PNA-SR oligo can efﬁciently modulate splice site selection
20 in the bcl-x gene in vivo and induce apoptosis in HeLa cells.
MATERIALS AND METHODS
Plasmid constructions
pBK-bclx was generated by amplifying human genomic DNA
with the primer pairs MC35.21 (50-AGATATCTAGAATGT-
25 CTCAGAGCAACCGGGAGCTG), MC36.11 (50-ATAGCG-
AATTCCAATCACCCAACACAACAGAAAGAG), MC36.12
(50-ATAGCGAATTCCCACCCACCTACATCACTCTCTG-
AG) and MC36.13 (50-TAGATCTCGAGCACAGTCATGC-
CCGTCAGGAACCAG). The PCR products were then inser-
30 ted in pBluescript KS+ under the T7 polymerase promoter.
The construct pBK-bclx-PM was generated by PCR-mediated
site directed mutagenesis of pBK-bclx utilizing the primers
MC35.37 (50-CACCCTAGCGAGAGTATATCAGAGCTTT-
GAACAG) and MC35.38 (50-TGATATACTCTCGCTAGG-
35 GTGATGTGGAGCTGGGA).
In vitro pre-mRNA splicing assays and
preparation of SR proteins
Capped,
32P-labeled run-off transcripts were synthesized by
in vitro transcription using T7 RNA polymerase. HeLa cell
40 and S100 extracts were prepared as described previously (17).
In vitro splicing reactions were performed in a total volume of
25 ml, containing 15 ml of HeLa cell nuclear extract or S100 as
described previously (17). The reaction mixtures were incub-
ated at 30 C for 2 h. RNAs recovered from the reaction mix-
45 tures were separated on an 8 M urea–6% polyacrylamide gel
and visualized with a Kodak 200R Image Station. Splicing
ratios were calculated adjusting for the relative length of the
spliced and unspliced RNA products. SR proteins were pre-
pared from HeLa cellsand calf thymus as described previously
50 (18), except for SF2/ASF that was graciously donated by
DrAdrianKrainer,ColdSpringHarborLaboratory.SRproteins
werenormalizedforsplicingactivityonab-globinsubstrateas
described previously (19). Approximately 200 ng of each SR
protein, puriﬁed from calf thymus, or 500 ng of a total SR
55 protein preparation from HeLa cells was added to the splicing
mixture as indicated in Figure 2. All PNA, PNA-SR and SR
peptides were synthesized and high-performance liquid chro-
matography puriﬁed by Oswald Scientiﬁc.
Transfection of PNA-SR oligos and RT–PCR
60 HeLa cells were maintained at below 80% conﬂuence in D-
MEM (Gibco BRL) supplemented with 5% calf serum and
antibiotics. Cells were seeded 24 h before treatment at 40%
conﬂuence in a 24-well plate. At the time of transfection,
growth media was removed and replaced with fresh media
65 not containing serum or antibiotics. In addition, a mixture
of Lipofectamine 2000 (Invitrogen) and oligos was added
to the cells. After 5 h, growth media containing the transfec-
tion mixture was replaced with fresh media containing serum
and antibiotics. Cells were harvested 48 h after transfection.
70 Total RNA was extracted with Trizol (Invitrogen), reverse
transcribed utilizing a poly(dT) oligonucleotide, and PCR
ampliﬁed with primers MC21.50 (50-GCGCTGAGGGAG-
GCAGGCGAC) and MC36.13 for 32 cycles. PCR products
were visualized and quantiﬁed with a Kodak 200R Image
75 Station. Splicing ratios were calculated adjusting for the rel-
ative length of the spliced and unspliced PCR products.
Western blot analysis
HeLa cells were transfected as described above and 24 h post-
transfection, cells were scraped from six-well plates into the
80 media, washed twice with phosphate-buffered saline and
resuspended in 80 ml of SDS–polyacrylamide gel electrophor-
esis sample buffer. Samples were subjected to electrophoresis
on a SDS–12% polyacrylamide gel and transferred to a PVDF
membrane (Immobilon  P, Millipore). Membranes were
85 immunoblotted using a rabbit anti-bcl-x polyclonal antibody
S18 (Santa Cruz Biotech) or a rabbit anti-hnRNP H/H0 poly-
clonal kindly provided by Dr D. L. Black (University of
California, Los Angeles) and visualized by chemilumines-
cence (ECL -system, Pierce).
90 Annexin-V/propidium iodide staining
HeLa cells were transfected as described above with 5 mMo f
PNA-(SR)8, PNA oligo control or (SR)8 polypeptide per well.
Twenty-four hours post-transfection, cells were stained with
Annexin-V and propidium iodide using the Annexin-V-Fluos
95 Staining Kit (Roche) following the manufacturer’s instruc-
tions. Annexin-V and propidium iodide staining were then
detected by microscopy using a FITC ﬁlter (Zeiss inverted
microscope-Axiovert 40 CFL).
RESULTS
100 SF2/ASF and SC35 activate bcl-x splicing
A combination of exonic silencers, exonic enhancers and
intronicregulatory elementshasbeen showntoregulatealtern-
ative splicing of the bcl-x gene in response to a variety of
stimuli (Figure 1A) (20,21). To date, hnRNPs H and F are
105 the only splicing factors found to bind one of those elements to
regulate splicing (B2G in Figure 1A) (21).
To gain insight into the regulation of bcl-x splicing, we
constructed a minimal bcl-x splicing substrate containing
the coding regions of exons 2 and 3 with a shortened inter-
110 vening intron (Figure 1A). All the exonic splicing regulatory
6548 Nucleic Acids Research, 2005, Vol. 33, No. 20sequences previously characterized (20,21) are present in the
pBK-bclx splicing substrate, whereas only part of the Intronic
responsive element (IRE in Figure 1A) is present (22). Addi-
tion of further intronic sequences to include the entire IRE did
5 not alter the bcl-xL/-xS splicing ratio (data not shown). In vitro
splicing in HeLa nuclear extracts of the pBK-bclx substrate
generated two spliced products corresponding to the bcl-xL
and bcl-xS isoforms. The 12.8 ratio between the two isoforms
(Figure 1B) is remarkably similar to the 11.4 bcl-xL/-xS ratio
10 of the endogenous gene in HeLa cells (Figure 1C).
Members of the SR protein family are arguably the best
characterized regulators of splicing. Single SR proteins have
been shown to have similar, yet distinct substrate speciﬁcities
and thus can differentially promote splicing of a given sub-
15 strate or splice site. Nevertheless, SR proteins also operate as a
constitutive part of the splicingmachinery and are essential for
the splicing of all transcripts (15,23,24). To determine whether
speciﬁc SR proteinswereinvolved inthe splicing regulationof
the bcl-x gene, the pBK-bclx splicing substrate was incubated
20 in HeLa S100 cytoplasmic extracts complemented with single
SR proteins. S100 extracts are depleted of SR proteins, thus
splicing reactions performed with such extracts are not efﬁ-
cient. However, complementation with SR proteins has been
shown to restore the ability of S100 extracts to activate spli-
25 cing (23,25). Splicing of pBK-bclx was only slightly activated
by complementation by SRp40, SRp55 or SRp75 (Figure 2,
lanes 6–8). In contrast, complementation by a mixture of all
SR proteins, SF2/ASF or SC35 activated splicing of the pBK-
bclx substrate to levels similar to that obtained with nuclear
30 extract (Figure 2, lanes 3–5).
Addition of SF2/ASF or SC35 to the splicing deﬁcient S100
extracts didnotsigniﬁcantly alter the bcl-xL/-xSratio, 14.2 and
11.8, respectively (versus 12.8 when incubated with nuclear
extract). This indicates that SF2/ASF and SC35 may play a
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Figure 1. Alternative splicing of bcl-x.( A) Schematic representation of the bcl-x gene and of the bcl-xL and bcl-xS alternatively spliced transcripts. Cis-regulatory
sequences that act as splicing enhancers or silencers are indicated. The in vitro splicing construct used in this study, pBK-bclx, is schematically represented.
(B)InvitrosplicingofpBK-bclx.Radiolabeledpre-mRNAsubstrateswereincubatedinHeLanuclearextract.RNAprecursorsandsplicedproductsareindicatedby
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RT–PCR. Splicing ratios and error bars have been obtained from three independent experiments.
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notselectively directsplicingtowardoneof thetwo alternative
50 splice sites. We also cannot exclude the hypothesis that a SR
protein different from the ones tested is speciﬁcally promoting
5 splicing at one of the two alternative 50 splice sites.
A chimeric PNA-SR oligo activates bcl-xS in vitro
To enhance the splicing of the bcl-xS isoform, a chimeric PNA
oligo tethered to eight Ser-Arg (SR) repeats was made com-
plementary to a site 20–31 nt upstream of the bcl-xS 50 splice
10 site (Figure 3A). The addition of the PNA-SR oligo to the
in vitro splicing reactions in HeLa nuclear extract caused a
dramatic dose-dependent switch in the bcl-xL/-xS ratio from
12.8 to 0.3 (Figure 3B, lanes 1–4). The switch in isoform ratio
occurred at a compound concentration of 0.5–5 mM. Splicing
15 was unaffected by a control PNA oligo lacking the (SR)8
domain (Figure 3B, lanes 5–7) or by the (SR)8 peptide
alone (Figure 3B, lanes 8–9), demonstrating that both the
antisense PNA targeting domain and the SR domain were
required.
20 Regulatory sequences that either upregulate or downregu-
late splicing are often found in close proximity to the splice
site they regulate (26). The absence of an effect by the PNA
oligo control indicates that no other regulatory factors bind in
the same region targeted by the antisense oligonucleotide.
25 Nevertheless, to verify that no regulatory sequence is present
in the region targeted by the PNA-SR antisense oligo, we
mutated the splicing substrate (pBK-bclx-PM in Figure 3A).
The wild-type pBK-bclx and mutant pBK-bclx-PM substrates
splice with similar efﬁciency (12.8 and 13.7, respectively),
30 thus conﬁrming that no ESE or ESS sequences are present
in the region targeted (Figure 3B). Additionally, the PNA-SR
oligo, the PNA alone and the (SR)8 peptide alone all had no
effect on the splicing of the mutant pBK-bclx-PM substrate
(data not shown).
35 The PNA-SR oligo can modulate bcl-x splicing in vivo
Since the chimericPNA-SR oligo was able to dramaticallyand
speciﬁcally switch splicing to the bcl-xS isoform in vitro,w e
investigated the possibility that this oligo would also alter the
bcl-xL/-xS ratio in HeLa cells. The PNA-SR oligo was trans-
40 fected into HeLa cells by cell scraping, spontaneous uptake
and Lipofectamine. Transfection by Lipofectamine caused a
dose-dependent switch in the bcl-xL/-xS ratio, at both the RNA
and protein levels, when cells were transfected with a 10 mM
solution of the PNA-SR oligo (Figure 4A, lanes 1–4 and
45 Figure 4B, lanes 1–3), while no change was observed when
cells were transfected by spontaneous uptake or cell scraping
at concentrations up to 50 mM (data not shown). Using
Lipofectamine, the bcl-xL/-xS mRNA ratio decreased from
11.4 in untreated cells to 4.9 when the PNA-SR oligo was
50 added to a ﬁnal concentration of 50 mM. The PNA-SR oligo
effect on the bcl-xL/-xS ratio was highly speciﬁc since neither
the PNA oligo alone nor the (SR)8 peptide alone affected bcl-x
splicing (Figure 4A, lanes 5–8 and Figure 4B lanes 4–7). This
is the ﬁrst demonstration that PNA-SR oligos can modulate
55 splicing in vivo.
Modulation of splicing by PNA-SR oligos induces
apoptosis in HeLa cells
The short isoform (bcl-xS) of the bcl-x gene is known to have
pro-apoptotic properties. To study the effect that alteration of
60 the bcl-xL/-xS ratio by the PNA-SR oligo had on the trans-
fected cells, we utilized Annexin-V and propidium iodide
staining to detect apoptosis-mediated cell death and necrosis.
During apoptosis, cells breakup the phospholipid symmetry of
their plasma membrane and expose phosphatidylserine on the
65 external side of the lipid bilayer. Annexin-V preferentially
binds to negatively charged phospholipids like phos-
phatidylserine and thus can be used to detect cells undergoing
apoptosis. Following transfection with the bcl-x-speciﬁc PNA-
(SR)8 oligo, cells showed a much higher level of apoptosis
70 than cells that were transfected with the PNA alone or (SR)8
peptide control (Figure 5). The increased level of apoptosis
was evident 24 h after transfection, whereas no increase in the
level of necrotic cells was detected (data not shown). The
chimeric PNA-SR oligo thus speciﬁcally triggers apoptosis
75 in HeLa cells.
DISCUSSION
Utilizing the bcl-x gene as a model, we have shown that chi-
meric antisense PNA oligos conjugated to an SR domain can
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6550 Nucleic Acids Research, 2005, Vol. 33, No. 20modulate splicing patterns independent of the existence of an
SR-dependent-exonic splicing enhancer and that they can be
efﬁciently delivered in vivo to trigger apoptosis in HeLa cells.
SRproteinsare important regulators ofalternativesplicingand
5 two members of this family, SF2/ASF and SC35, up-regulate
splicing of the bcl-x substrate. Nevertheless, SF2/ASF and
SC35 did not promote speciﬁc splice site selection in this
alternative 50 splice site system.
Although SR proteins do not appear to be involved in regu-
10 lating splice site choice in bcl-x, we showed that a chimeric
oligo mimicking SR protein activity (PNA-SR) targeted
upstream of the bcl-xS 50 splice site did redirect the splicing
machinery, inducing a dramatic switch in the ratio between the
bcl-xL and bcl-xS isoforms. The use of PNA-SR compounds
15 was developed previously by Cartegni and Krainer (14) who
utilized in vitro splicing substrates derived from the SMN2 and
BRCA1 genes. In that study, the PNA-SR compounds were
targeted to a sequence immediately downstream of the 50
splice site to restore inclusion of a skipped exon (14). In
20 contrast, the sequence we targeted in bcl-x is located upstream
of a 50 splice site and the PNA-SR oligo causes that splice site
to become preferentially utilized over a downstream 50 splice
site. The different kinds of splicing regulation induced, as well
as the different positioning of the oligos in these systems,
25 underscore the versatility of this technique.
Control PNA oligos not carrying the SR peptide have been
shown to activate splicing when targeted to the BRCA1 and
SMN2 substrates, although requiring a PNA oligo concentra-
tion 5–10 times higher to achieve comparable effects to the
30 PNA-SR oligo (14). For bcl-x, we found that the PNA alone
control oligo had no effect in vitro, even at a concentration of
5 mM. The discrepancy in the effect of the control PNA oligos
between the bcl-x and the BRCA1 and SMN2 substrates can be
explained, at least for the SMN2 substrate, with the fact that
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Nucleic Acids Research, 2005, Vol. 33, No. 20 6551binding of the control PNA to the SMN2 substrate masks the
binding site for hnRNP A1, a negative regulator of splicing
(27), thus de-repressing splicing.
Transfection of antisense oligonucleotides to block the use
5 of the bcl-xL 50 splice site has been shown to efﬁciently alter
the bcl-xL/-xS splicing ratio at a concentration of 1 mM
(12,13). Additionally, antisense oligos that contain protein
binding sites as part of a non-hybridizing 50 tail targeted
upstream of the bcl-xL 50 splice site have been shown to
10 alter the splicing ratio in the nM range (28). Here, we showed
that a detectable change in the bcl-xL/-xS ratio in vivo is
observed upon transfection of cells with the PNA-SR oligo
at a concentration higher than 10 mM. Rather than blocking the
bcl-xL 50 splice site as previous studies have done, we activ-
15 ated splicing to bcl-xS and thus a high concentration of PNA-
SR oligo may be needed to overcome the active mechanism
repressing use of the bcl-xS 50 splice site. Furthermore, it is
possible that the chimeric PNA-SR oligonucleotide cannot
efﬁciently cross the cellular and/or the nuclear membranes.
20 Conjugation of the PNA-SR oligo with translocation peptides
or to several positively charged residues (29) may be used to
facilitate the absorption through the membranes and the nuc-
lear localization of these oligos.
Nevertheless, our data shown in Figure 5 indicate that the
25 PNA-SR oligo can induce apoptosis in HeLa cells by altering
the bcl-xL/-xS ratio. Apoptosis is detected by 24 h after trans-
fection of the cells with a 5 mM solution of the PNA-SR oligo.
This concentration of PNA-SR oligo is much lower than the
one utilized to observe a marked shift in the bcl-xL/-xS ratio at
30 the RNA and protein levels (Figure 4). It is possible that only a
sub-population of cells is transfected with high efﬁciency by
the PNA-SR oligo, and thus the non-transfectedcells dilute the
effect of the splicing ratio switch. Furthermore, cells that are
transfected with highefﬁciencypresumablyundergoapoptosis
35 and degrade their mRNAs and proteins at much higher levels
than the untransfected healthy cells, thus interfering with a
direct analysis of the bcl-xL/-xS ratio switch.
PNAs have a neutral peptide-like backbone, form highly
stable and speciﬁc base pairing with RNA, are resistant to
40 nucleases, do not trigger RNase H activity and can be easily
conjugated with any polypeptide (16). Furthermore, PNA oli-
gos have been successfully delivered into cells in culture and
into animal tissues (30). All these characteristics make these
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6552 Nucleic Acids Research, 2005, Vol. 33, No. 20compounds ideal for their use as therapeutic agents. Not only
can PNA-SR oligos modify the expression of single protein
isoforms, but they also have the potential to generate novel
mRNAs coding for new proteins. This would further increase
5 the diversity of the proteome and possibly lead to new thera-
peutic tools.
In particular, it is conceivable that PNA-SR oligos could be
targeted to activate cryptic splice sites that closely match the
consensus sequence but are normally not used in vivo. The
10 splicing machinery often does not recognize such splice sites
because splicing enhancers within close proximity are often
required for a splice site to be active. Accordingly, we have
previously shown that even a perfect consensus 50 splice site
cannot splice without the presence of a nearby ESE in a viral
15 transcript (31). Targeting a PNA-SR oligo in proximity of a
cryptic splice site could activate such site, thus generating
novel gene products.
An example for such applications could be the bcl-2 gene,
an inhibitor of apoptosis. Despite its high homology at the
20 nucleotide level with bcl-x, the bcl-2 gene is not alternatively
spliced into a short and a long isoform like bcl-x.T h ebcl-xS 50
splice site sequence AG/GUAGUG is similar to the corres-
pondingsequence present inthebcl-2geneCG/GUGGUG that
is never utilized, but is close to the consensus 50 splice site AG/
25 GURAGU. Therefore, it may be possible to use a PNA-SR
oligo targeted to that region of bcl-2 to create a novel bcl-2
isoform that encodes a protein that is likely to have pro-
apoptotic properties. PNA-SR oligos have the potential to
change not only known splicing patterns, but also to create
30 novel gene products in cellular and possibly animal systems.
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